Cross Country Healthcare, Inc. (CCRN)
NASDAQ: CCRN · Real-Time Price · USD
13.10
-0.03 (-0.23%)
May 18, 2026, 4:00 PM EDT - Market closed
Cross Country Healthcare Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Cross Country Healthcare stock has a consensus rating of "Hold" and an average price target of $12.44. The average 1-year stock price forecast is 5.04% lower than the current stock price, while the lowest is $10 (-23.66%) and the highest is $13.25 (+1.15%).
Price Target: $12.44 (-5.04%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Cross Country Healthcare stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 1 | 1 | 0 |
| Hold | 3 | 3 | 4 | 2 | 2 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $10 → $13 | Hold | Maintains | $10 → $13 | +1.15% | May 11, 2026 |
| Benchmark | Benchmark | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 8, 2026 |
| Wedbush | Wedbush | Buy → Hold Downgrades $15 → $13 | Buy → Hold | Downgrades | $15 → $13 | +1.15% | May 7, 2026 |
| Wedbush | Wedbush | Hold → Buy Upgrades $11 → $15 | Hold → Buy | Upgrades | $11 → $15 | +14.50% | Mar 19, 2026 |
| Benchmark | Benchmark | Hold → Strong Buy Upgrades $14 | Hold → Strong Buy | Upgrades | $14 | +6.87% | Mar 5, 2026 |
Financial Forecast
Revenue This Year
996.07M
from 1.05B
Decreased by -5.52%
Revenue Next Year
1.05B
from 996.07M
Increased by 5.01%
EPS This Year
0.11
from -2.93
EPS Next Year
0.28
from 0.11
Increased by 148.98%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.0B | 1.1B | |||
| Avg | 996.1M | 1.0B | |||
| Low | 941.9M | 982.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.5% | 11.1% | |||
| Avg | -5.5% | 5.0% | |||
| Low | -10.7% | -1.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.18 | 0.42 | |||
| Avg | 0.11 | 0.28 | |||
| Low | 0.03 | 0.20 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 278.1% | |||
| Avg | - | 149.0% | |||
| Low | - | 76.5% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.